Most GLP-1 programs are built around the prescription. But the prescription isn't where outcomes are won or lost. Real-world adherence looks nothing like clinical trials. Behavioral health challenges, untreated comorbidities, the emotional complexity of changing your relationship with food. These are the variables that determine whether GLP-1 coverage becomes a sustainable investment or a rising cost with diminishing returns. Join Goodpath's clinical and pharmacy leaders on 3/24 to unpack what sustainable GLP-1 coverage actually requires. Dr. Nishant (Nishu) Uppal Medical Director Dr. James Lyda, Ph.D. Director of Mental Health Aaron Wurst Pharmacy Benefits Expert The session covers the gap between trial data and real-world results, why behavioral health is the hidden variable in GLP-1 ROI, and what 10-15 next-generation anti-obesity medications in trial mean for employers planning ahead.

📣Benefits leaders! Make sure you are choosing the right GLP-1 strategy. Check out Goodpath and why a whole body and integrative approach is key to successful, long lasting outcomes and ROI return. #strategy March 24, 2-3pm ET. Register here: https://lnkd.in/ds7HbW3S

The FDA sent 50+ warning letters to supplement companies last year. The #1 reason? Unsubstantiated health claims. Here's the pattern I keep seeing: ❌ "Cures arthritis" — disease claim, instant violation ❌ "Clinically proven to..." — without actual clinical evidence ❌ "Treats anxiety" — implied drug claim ❌ "Doctor recommended" — without documentation What the FDA actually requires: ✅ Structure-function claims only ("supports joint health") ✅ Competent, reliable scientific evidence ✅ Studies on healthy human subjects ✅ Oral administration in relevant doses The fix isn't complicated. It's just time-consuming. Unless you automate it. What's the most questionable supplement claim you've seen lately? #DietarySupplements #FDACompliance #SupplementIndustry #StructureFunctionClaims #NutraComp

“When prescriptions become harder to access or more expensive, patients struggle to follow their treatment plans. Blood pressure rises. Diabetes goes unmanaged. Preventable complications increase. The cost is human first, financial second.” Check out this powerful opinion piece by Jessica Yanow, AACHC President and CEO, as she highlights why protecting the 340B drug program is vital for public health. https://lnkd.in/e2VNgSqV

New blog: Why GLP-1 patients drop off after 60 days and what clinics can do to reduce churn. Insights on behavior patterns, touchpoint timing, and scalable interventions clinics can implement to sustain adherence. Read the article: https://wix.to/xDBvTOd #GLP1 #PatientEngagement #HealthcareStrategy #ClinicOperations

You’ve likely heard about GLP-1 medications, even if you’ve never taken them. Today, GLP‑1 medications are part of everyday conversations. You’re likely to know someone who takes one – or you may be wondering whether you should. They are part of a new era in weight loss science, and one of the most talked‑about developments in modern health care. But how do you know if a GLP‑1 is right for you? At Medcan, our physicians walk clients through GLP-1 benefits, risks, and considerations every day to support evidence-informed decision-making. So, this month we interviewed three of them: a globally recognized leader in obesity, a diabetes specialist, and a medical senior leader who is one of our Dedicated Care physicians. To stay informed and for clear, credible insights read our latest guide: GLP‑1s, from a doctor’s lens: what they do, who should consider them, and what’s next. Learn more here: https://lnkd.in/gk2283k8 Note: This information is intended for educational purposes and is not a substitute for professional medical advice, diagnosis, or treatment.

Employers are under pressure to offer GLP-1s but need options that won’t blow up budgets. Omada’s new GLP-1 Flex Care adds a path for employers to support obesity care while keeping medication spend outside the plan. With GLP-1 Flex Care, eligible members receive clinical evaluation, lab ordering, prescribing of FDA-approved GLP-1 medications, and ongoing virtual care and lifestyle support. Members then purchase medications independently through reputable cash-pay channels, helping employers limit direct exposure to medication costs. Why should benefits leaders care? GLP-1 demand is growing, and this model adds room to maneuver as pricing and coverage policies continue to shift—without forcing a choice between access and affordability. Want a GLP-1 path that fits your current benefit design? Learn more in our GLP-1 Flex Care announcement: https://lnkd.in/eVD4A7mc

The FDA is taking another step in the fight against the opioid crisis. The agency has issued a Request for Information (RFI) seeking public input on new standards for in-home opioid disposal products— potentially expanding beyond the current mail-back and take-back programs. Unused opioids at home pose a serious risk — both for those struggling with misuse and for family members with no prior exposure. The FDA’s goal: make safe disposal more accessible, reduce diversion, and strengthen community safety. Healthcare providers, manufacturers, and patient advocates are encouraged to share feedback before April 6. 💡 This initiative supports broader national efforts to prevent opioid misuse and promote public health. Read more: https://lnkd.in/gM_dQfd5 #FDANews #OpioidCrisis #PublicHealth #PatientSafety #HealthcareInnovation #Pharma #DisposalSolutions #AddictionPrevention #CommunityHealth #PolicyUpdate

The FDA is taking another step in the fight against the opioid crisis. The agency has issued a Request for Information (RFI) seeking public input on new standards for in-home opioid disposal products— potentially expanding beyond the current mail-back and take-back programs. Unused opioids at home pose a serious risk — both for those struggling with misuse and for family members with no prior exposure. The FDA’s goal: make safe disposal more accessible, reduce diversion, and strengthen community safety. Healthcare providers, manufacturers, and patient advocates are encouraged to share feedback before April 6. 💡 This initiative supports broader national efforts to prevent opioid misuse and promote public health. Read more: https://lnkd.in/gM_dQfd5 #FDANews #OpioidCrisis #PublicHealth #PatientSafety #HealthcareInnovation #Pharma #DisposalSolutions #AddictionPrevention #CommunityHealth #PolicyUpdate

A recent study looked at over 50 million people and found that those using GLP-1 medications for diabetes saw 6% lower medical cost growth after 30 months compared to non-users. Plus, consistent use led to even bigger savings. Curious about what this means for employers? Check out the full article! #HealthcareInsights #GLP1Medications #EmployerBenefits